Technical Analysis for ELTX - Elicio Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | -8.03% | |
| 180 Bearish Setup | Bearish Swing Setup | -8.03% | |
| Volume Surge | Other | -8.03% | |
| Stochastic Reached Oversold | Weakness | -8.03% | |
| Wide Bands | Range Expansion | -8.03% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 9 hours ago |
| 1.5x Volume Pace | about 9 hours ago |
| 3x Volume Pace | about 9 hours ago |
| Up 5% | about 9 hours ago |
| Up 3% | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/09/2024
Elicio Therapeutics, Inc. Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002, to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005, a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P), a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines, adjuvants, and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Disease Solid Tumors Treatment Of Cancer Cell Therapy Immunotherapies Vaccines Vaccination Virology Hematological Cancers Anaplastic Lymphoma Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.45 |
| 52 Week Low | 2.96 |
| Average Volume | 49,189 |
| 200-Day Moving Average | 6.76 |
| 50-Day Moving Average | 8.32 |
| 20-Day Moving Average | 7.21 |
| 10-Day Moving Average | 6.36 |
| Average True Range | 0.82 |
| RSI (14) | 23.08 |
| ADX | 39.24 |
| +DI | 8.24 |
| -DI | 45.71 |
| Chandelier Exit (Long, 3 ATRs) | 6.05 |
| Chandelier Exit (Short, 3 ATRs) | 5.96 |
| Upper Bollinger Bands | 9.72 |
| Lower Bollinger Band | 4.70 |
| Percent B (%b) | -0.18 |
| BandWidth | 69.61 |
| MACD Line | -0.89 |
| MACD Signal Line | -0.54 |
| MACD Histogram | -0.3481 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.16 | ||||
| Resistance 3 (R3) | 5.22 | 4.82 | 4.93 | ||
| Resistance 2 (R2) | 4.82 | 4.47 | 4.79 | 4.85 | |
| Resistance 1 (R1) | 4.30 | 4.26 | 4.10 | 4.24 | 4.77 |
| Pivot Point | 3.91 | 3.91 | 3.81 | 3.87 | 3.91 |
| Support 1 (S1) | 3.38 | 3.56 | 3.19 | 3.32 | 2.79 |
| Support 2 (S2) | 2.99 | 3.34 | 2.96 | 2.71 | |
| Support 3 (S3) | 2.47 | 2.99 | 2.63 | ||
| Support 4 (S4) | 2.40 |
